Biocon slammed with OAI; Hong Kong looks to WuXi for ADC abilities; Tanvex Pharma launches CDMO services

Welcome to Endpoints News’ manufacturing roundup, where we bring you essential updates on new builds, collaborations and more.

This week we saw Biocon Biologics in communication with the FDA over an OAI (official action indication) after problematic inspections at its Malaysian facility and new platform launches from the likes of WuXi Biologics and Lallemand Health Solutions.

We zero in on multiple partnerships, including WuXi XDC boosting its bioconjugate capabilities in Hong Kong as well as a few launches and mergers.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。